^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TrastuRel (trastuzumab biosimilar)
i
Other names: R-TPR-016
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Reliance Life Sci
Drug class:
HER2 inhibitor
Related drugs:
almost5years
[VIRTUAL] RAPID REVIEW OF TRASTUZUMAB BIOSIMILARS COMPARED TO REFERENCE TRASTUZUMAB FOR BREAST CANCER TREATMENT IN NAIVE PATIENTS (ISPOR 2020)
RESULTS : We found four papers from three equivalence randomized clinical trials and one non-inferiority trial comparing four trastuzumab biosimilars (SB3, ABP 980, CT-P6 and R-TPR-016) with the reference biological drug. CONCLUSIONS : The evidence was inconclusive regarding the statistical equivalence of efficacy between trastuzumab biosimilars and their reference. On the other hand, safety proved comparable.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Herzuma (trastuzumab-pkrb) • Kanjinti (trastuzumab-anns) • TrastuRel (trastuzumab biosimilar)
Share via
